Clinical Observation on the Efficacy of Bufei Yangxin Formula in Treating Chronic Pulmonary Heart Disease in the Decompensated Stage
Objective:To analyze the clinical efficacy of Bufei Yangxin Formula in treating chronic pulmonary heart disease during the decompensated period.Methods:Collect 120 eligible subjects of chronic pulmonary heart disease who met the inclusion criteria from February 2020 to February 2022 in our hospital during the decompensated period.Using a simple randomized method,they were divided into a treatment group (traditional Chinese medicine decoction combined with Western medicine treatment)and a control group (conventional Western medicine treatment group),with 60 patients in each group.Compare the clinical efficacy,traditional Chinese medicine syndrome scores,cardiac function (bilateral atrioventricular diameter,PASP,LVEF,LVDF,RVEF),and serum indicators (NT proBNP)between the two groups.Results:The complete control rate in the treatment group (58.33％)was higher than that in the control group (36.67％),with a statistically significant difference(P<0.05).There was no statistically significant difference in the total effective rate between the two groups(P>0.05 );The traditional Chinese medicine syndrome score in the treatment group was lower than that in the control group,and the difference was statistically significant(P<0.05);The bilateral atrioventricular diameter,PASP,and NT proBNP in the treatment group were lower than those in the control group,while LVEF,LVDF, and RVEF were higher than those in the control group,with statistically significant differences(P<0.05).Conclusion:The effect of Bufei Yangxin Formula on controlling clinical symptoms of CPHD patients is significant,which helps to improve their heart function.
Chronic pulmonary heart diseasePeriod of loss of compensationBufei Yangxin FormulaLung functionCardiac function
万方数据
维普
